CDK4 and neuroblastoma: Consistent with the potential therapeutic efficacy of senescence induction, as suggested by these studies, the effects of Cyclin-Dependent Kinases 4 and 6 (CDK4/6) specific inhibitor Ribociclib (LEE011) which induced cell-cycle arrest and senescence in human neuroblastoma, is being investigated in clinical trials [41,42].